Gadobutrol in India—A Comprehensive Review of Safety and Efficacy. (7th September 2017)

• Record Type: Journal Article
• Authors: Endrikat, Jan; Anzalone, Nicoletta
• Is Part Of: Magnetic resonance insights. Number 10(2017)
• Publication Date: 2017-09-07
• Subjects: Magnetic resonance imaging -- gadobutrol -- safety -- efficacy; Diagnostic imaging -- Periodicals; Magnetic resonance imaging -- Periodicals; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Diagnostic Imaging; Diagnostic imaging; Magnetic resonance imaging; Electronic journals; Periodicals; Electronic journals; Periodicals; 538.3605
• DOI: 10.1177/1178623X17730048
• Languages: English
• ISSNs: 1178-623X

Abstract

Gadobutrol is a gadolinium (Gd)-based contrast agent for magnetic resonance imaging (MRI). In India, gadobutrol is approved for MRI of the central nervous system (CNS), liver, kidneys, breast and for MR angiography for patients 2 years and older. The standard dose for all age groups is 0.1 mmol/kg body weight. The safety profile has been demonstrated in 42 clinical phase 2 to 4 studies (>6800 patients), 7 observational studies, and by assessing pharmacovigilance data of 29 million applications. Furthermore, studies in children, adults, and elderly and in patients with impaired liver or kidney function did not show any increased adverse event rate. Diagnostic efficacy was demonstrated in numerous studies and various indications, such as diseases of the CNS, peripheral and supra-aortic vessels, kidneys, liver, and breast.